Torlak Signs Agreement on Obtaining of Technologies for Production of Sputnik V Vaccine

The minister without a portfolio in charge of innovations and technological development in the Government of Serbia and a co-chairman of the Intergovernmental Committee for Cooperation with Russia, Nenad Popovic, has announced that an agreement has been signed whereby the Russian side transfers the data on the procedures and technologies necessary for the production of the Sputnik V vaccine in Serbia to the Serbian side, the government announced.

The Institute of Virology, Vaccines and Sera “Torlak” has signed an agreement on the transfer of technologies with the Russian Direct Investment Fund and the Russian pharmaceutical company Generium, whereby the entire process is made possible.

Popovic emphasized that Torlak now had at its disposal the data related to the production of the Sputnik V vaccine, developed by the most reputable virology institute in Russia, Gamaleya.

– These are sensitive and confidential data that only partners who have immense mutual trust can exchange – the minister assessed and announced that three validation series of the Sputnik V vaccine would be produced at Torlak in April

According to him, samples from these validation series will be sent for quality control to the Gamaleya Institute in Moscow and, after the institute confirms the validity of the samples produced at Torlak, the institute in Serbia will start producing the vaccine.

– We expect this to happen by May 20 – Popovic said and pointed out that this would make Serbia the first country in Europe to start producing Sputnik V.

Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije

Institut Torlak

minister without a portfolio in charge of innovations and technological development in the Government of Serbia

Intergovernmental Committee for Cooperation with Russia

Institute of Virology Vaccines and Sera Torlak

Generium

Nenad Popovic

production of Sputnik V vaccine

vaccine

production of the Russian vaccine

coronavirus vaccine